

# Mouse CCL11/Eotaxin Biotinylated Antibody

Antigen Affinity-purified Polyclonal Goat IgG Catalog Number: BAF420

DESCRIPTION	
Species Reactivity	Mouse
Specificity	Detects mouse CCL11/Eotaxin in ELISAs and Western blots. In sandwich immunoassays, less than 0.5% cross-reactivity with recombinant human CCL11/Eotaxin and recombinant mouse CCL24/Eotaxin-2 is observed.
Source	Polyclonal Goat IgG
Purification	Antigen Affinity-purified
Immunogen	E. coli-derived recombinant mouse CCL11/Eotaxin (R&D Systems, Catalog # 420-ME) His24-Pro97 Accession # P48298
Formulation	Lyophilized from a 0.2 µm filtered solution in PBS with BSA as a carrier protein. See Certificate of Analysis for details.


### APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website

Tease Note: Optimal distributions should be determined by each laboratory for each application. Scholar Potocols are available in the Technical Information Section on our website.						
	Recommended	Sample				
	Concentration	·				
Western Blot	0.1 μg/mL	Recombinant Mouse CCL11/Eotaxin (Catalog # 420-ME)				
Immunohistochemistry	5-15 μg/mL	See Below				
Mouse CCL11/Eotaxin Sandwich Immunoassay		Reagent				
ELISA Capture	0.2-0.8 μg/mL	Mouse CCL11/Eotaxin Antibody (Catalog # AF-420-NA)				
ELISA Detection	0.1-0.4 μg/mL	Mouse CCL11/Eotaxin Biotinylated Antibody (Catalog # BAF420)				
Standard		Recombinant Mouse CCL11/Eotaxin (Catalog # 420-ME)				

#### DATA

## Immunohistochemistry



CCL11/Eotaxin in Mouse Colon.
CCL11/Eotaxin was detected in perfusion fixed frozen sections of mouse colon using Goat Anti-Mouse CCL11/Eotaxin Biotinylated Antigen Affinity-purified Polyclonal Antibody (Catalog # BAF420) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm. View our protocol for

Chromogenic IHC Staining of Frozen Tissue

PR	EP#	RAT	ION.	AND	STO	RAGE	

**Reconstitution** Reconstitute at 0.2 mg/mL in sterile PBS.

**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.

# BACKGROUND

CCL11 is a potent eosinophil chemoattractant that was originally purified from bronchoalveolar lavage fluid of guinea pigs sensitized by aerosol challenge with ovalbumin. Microsequencing of the purified protein revealed the guinea pig CCL11 to be a member of the beta (CC) chemokine family of inflammatory and immunoregulatory cytokines. cDNA clones for guinea pig, mouse and human CCL11 have been isolated. Mouse CCL11 cDNA encodes a 97 amino acid residue precursor protein from which the amino-terminal 23 amino acid residues are cleaved to generate the 74 amino acid residue mature mouse CCL11. At the protein sequence level, mature mouse CCL11 is approximately 60% identical to mature human and guinea pig CCL11. In addition, mouse CCL11 also shows high amino acid sequence identity to members of the MCP family. Mouse CCL11 is chemotactic for eosinophils, but not mononuclear cells or neutrophils. CCL11 mRNA is expressed in a variety of tissues. The expression of CCL11 mRNA is induced in cultured endothelial cells in response to IFN-y. In addition, CCL11 mRNA is also induced in response to the transplantation of IL-4-secreting tumor cells. The CC chemokine receptor 3 (CCR3) has now been identified to be a specific human CCL11 receptor.

### References:

- 1. Rothenberg, M.E. et al. (1995) Proc. Natl. Acad. Sci. USA 92:8960
- 2. Kitaura, M. et al. (1996) J. Biol. Chem 271:7725.
- 3. Garcia-Zepeda, E.A. et al. (1996) Nature Medicine 2:449.
- 4. Ponath, P.D. et al. (1996) J. Clin. Invest. 97:604.

Rev. 2/6/2018 Page 1 of 1

